When daily oral PrEP launched, it was a revolution. An injection every two months with CAB-LA made adherence even easier. Lenacapavir goes further still: two injections a year, six months apart, giving continuous HIV protection with a lower dosing burden than any prevention method that has ever existed.

The PURPOSE 1 and PURPOSE 2 trials, published in 2024, produced results that genuinely shocked the HIV prevention community. PURPOSE 1, which enrolled young women in sub-Saharan Africa, found zero new HIV infections among the 2,134 participants on lenacapavir PrEP. Not fewer infections. Zero. PURPOSE 2 followed a broader population including men who have sex with men, transgender women, and non-binary people, and found similarly near-complete protection. These are among the strongest efficacy results ever reported in HIV prevention research.

A word on access before we go further. Lenacapavir is the newest of all the PrEP options, and it’s also the least widely available. Rollout across Nigeria and much of sub-Saharan Africa is at the earliest stage, with supply still limited. This guide explains what it is, how the schedule works, the side effects, and who it suits best, so you understand it fully. If you want to know whether you can access it right now, message our team and we’ll tell you honestly where things stand rather than promise something we can’t yet reliably deliver.

The three PrEP options and how they compare.

Lenacapavir represents the logical endpoint of the long-acting PrEP trajectory: the fewest interventions possible for maximum continuous protection. For anyone who finds even a bimonthly clinic visit burdensome, or whose life is structured in a way that makes scheduled clinic appointments difficult, twice-yearly dosing removes almost all of that friction.

The mechanism and why it is different from other PrEP options.

Lenacapavir belongs to a new class of antiretroviral drug called capsid inhibitors, the first of its kind approved for any HIV indication. Where oral PrEP (TDF/FTC) blocks two specific steps in HIV’s replication cycle, and cabotegravir blocks a different single step, lenacapavir targets the HIV capsid, the protein shell that surrounds and protects the virus’s genetic material. By disrupting the capsid at several points in HIV’s lifecycle at once, lenacapavir creates a higher barrier to resistance than most other antiretroviral drugs.

The long-acting formulation is given as a subcutaneous injection, meaning it is injected just beneath the skin (usually in the abdomen) rather than deep into muscle as with CAB-LA. The drug forms a depot under the skin that slowly releases into the bloodstream over approximately six months, maintaining protective concentrations throughout.

What the twice-yearly schedule looks like in practice.

What to expect from lenacapavir injections.

The most common side effect is an injection site nodule, a small, firm lump under the skin at the injection site that forms as the drug depot establishes itself. This is expected, generally painless after the first week, and typically resolves over several months. It is not a sign of infection or an allergic reaction. Your nurse will tell you to expect it before your first injection.

Injection site redness, swelling, or tenderness is also common in the first one to two weeks after the injection, particularly after the loading doses. These side effects are usually mild and self-limiting.

Systemic side effects, headache, nausea, fatigue, have been reported in a small proportion of people in clinical trials but are generally uncommon and less frequent than with oral PrEP. Lenacapavir does not carry the kidney or bone mineral density considerations associated with Tenofovir-based oral PrEP.

If you notice significant swelling, spreading redness, warmth, or discharge from the injection site beyond the first week, contact our team or a nurse promptly. These could point to a local infection that needs treatment.

The people who benefit most from twice-yearly dosing.

• People who have struggled to maintain daily oral PrEP adherence despite genuine effort, irregular routines, frequent travel, shift work, or lifestyle factors that consistently interrupt the daily habit.
• People for whom complete privacy is essential and who cannot keep a daily pill or even a bimonthly clinic visit schedule discreet. Two visits per year is far easier to manage without detection than daily medication or monthly clinic visits.
• People who want the absolute lowest-burden prevention option that currently exists, particularly for long-term use where daily pill fatigue becomes a genuine adherence risk over years.
• People in high-risk environments where continuous, guaranteed protection is essential and adherence to oral PrEP cannot be reliably assured, including healthcare workers in high-HIV-burden settings, sex workers, and people in serodiscordant relationships without consistent access to their medication supply.
• Young women in sub-Saharan Africa, the population with the highest HIV incidence globally, and the group in whom lenacapavir produced the PURPOSE 1 trial’s historic zero-infection result.

Questions about lenacapavir in Nigeria.